Recent Trends in the Management of High-Risk Non–Muscle-Invasive Bladder Cancer: A Review Article
Nisanth Puliyath, Subeesh Parol, T. C. Farzana, K. V. Shanmugh Das, A. V. VenugopalanAbstract
Background:
High-risk nonmuscle-invasive bladder cancer (NMIBC) presents a persistent clinical challenge due to its aggressive rate of recurrence and progression, requiring intensive therapeutic intervention and rigorous follow-up.
Objective:
This comprehensive review examines the latest diagnostic breakthroughs, advanced therapeutics, and digital health milestones reshaping high-risk NMIBC care.
Materials and Methods:
In June 2025, a systematic literature search was executed via the Medline (PubMed) database. The screening targeted high-level clinical evidence—including randomized controlled trials, systematic reviews, and meta-analyses—published over the last decade to capture modern practice patterns.
Results:
To overcome the visual limitations of traditional white-light cystoscopy, clinicians are increasingly adopting advanced optical platforms like photodynamic diagnosis and narrow-band imaging to maximize tumor detection and optimize resection margins. While surgical resection followed by intravesical Bacillus Calmette–Guérin (BCG) remains the foundational guideline-backed regimen, innovative delivery platforms such as the TAR-200 continuous-release system and conductive chemohyperthermia are expanding the intravesical armamentarium. For the historically difficult-to-treat BCG-unresponsive cohort, the therapeutic landscape has expanded with recent Food and Drug Administration approvals of systemic pembrolizumab and viral-mediated gene therapy (nadofaragene firadenovec), offering viable bladder-sparing pathways. Concurrently, post-treatment surveillance is transitioning toward noninvasive monitoring through a diverse suite of urine-based assays tracking messenger RNA expression, DNA methylation, and key genetic mutations. Paralleling these molecular tools, machine learning and radiomic algorithms are demonstrating superior predictive capabilities in forecasting specific patient recurrence trajectories.
Conclusion:
The clinical management of high-risk NMIBC is undergoing a rapid paradigm shift. By bridging advanced optical imaging, diversified multi-mechanism salvage therapies, non-invasive liquid biopsies, and predictive artificial intelligence models, modern oncology can increasingly offer personalized care strategies that safely defer or avoid early radical cystectomy.